Study of Pembrolizumab (MK-3475) vs Standard Therapy in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (MK-3475-177/KEYNOTE-177)

Name: Study of Pembrolizumab (MK-3475) vs Standard Therapy in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (MK-3475-177/KEYNOTE-177)
Published: 2015
License: Public Domain

Merck Sharp & Dohme LLC · 2015

ClinicalTrials.gov · Datasets · License: Public Domain · 2015

Open Source ↗

colorectal carcinoma, programmed cell death receptor 1 (pd-1), programmed cell death receptor ligand 1 (pd-l1, pdl1), interventional, phase3

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Study of Pembrolizumab (MK-3475) vs Standard Therapy in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (MK-3475-177/KEYNOTE-177)

Related documents